Skip to main content

Advertisement

SpringerLink
Log in

Immunologic approaches to therapy for brain tumors

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Malignant brain tumors are notoriously invasive. Although surgical debulking can relieve the patient of the main mass of tumor, adjuvant treatments are needed to target the glioma cells that infiltrate through normal parenchyma as single cells or pockets of tumor cells from which recurrent tumors arise. Successful adjuvant cellular therapy of brain tumors, or activation of endogenous immune cells, requires that either cell effectors make direct contact with tumor cells or come within close proximity to them and exert an indirect effect. This review examines current clinical trials aimed at direct lysis of glioma cells and trials making gliomas more visible to the endogenous immune system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Prados MD, Berger MS, Wilson CB: Primary central nervous system tumors: advances in knowledge and treatment. Ca Cancer J Clin 1998, 48:331–360.

    PubMed  CAS  Google Scholar 

  2. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 2000, 27:S1-S10.

    Google Scholar 

  3. Burger PC, Schiethauer BW, Vogel SS: Surgical Pathology of the Nervous System and Its Coverings. New York: Churchill Livingston; 1991.

    Google Scholar 

  4. Giese A, Laube B, Zapf S, et al.: Glioma cell adhesion and migration on human brain sections. Anticancer Res 1998, 18:2435–2447.

    PubMed  CAS  Google Scholar 

  5. Silbergeld DL, Chicoine MR: Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997, 86:525–531.

    PubMed  CAS  Google Scholar 

  6. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 1998, 44:691–695.

    Article  PubMed  CAS  Google Scholar 

  7. Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998, 70:1781–1792.

    Article  PubMed  CAS  Google Scholar 

  8. Shapiro JR, Yung WK, Shapiro WR: Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 1981, 41:2349–2359.

    PubMed  CAS  Google Scholar 

  9. Baker DG, Krochak RJ: The response of the microvascular system to radiation: a review. Cancer Invest 1989, 7:287–294.

    PubMed  CAS  Google Scholar 

  10. Gage FH: Mammalian neural stem cells. Science 2000, 287:1433–1438.

    Article  PubMed  CAS  Google Scholar 

  11. Pincus DW, Goodman RR, Fraser RA, et al.: Neural stem and progenitor cells: a strategy for gene therapy and brain repair. Neurosurgery 1998, 42:858–867.

    Article  PubMed  CAS  Google Scholar 

  12. Kruse CA, Mitchell DH, Lillehei KO, et al.: Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer 1989, 64:1629–1637.

    Article  PubMed  CAS  Google Scholar 

  13. Elliott L, Brooks W, Roszman T: Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 1987, 78:919–922.

    PubMed  CAS  Google Scholar 

  14. McVicar DW, Davis DF, Merchant RE: In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 1992, 76:251–260.

    Article  PubMed  CAS  Google Scholar 

  15. Liau LM, Black KL, Prins RM, et al.: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999, 90:1115–1124.

    PubMed  CAS  Google Scholar 

  16. Heimberger AB, Crotty LE, Archer GE, et al.: Bone marrowderived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000, 103:16–25.

    Article  PubMed  CAS  Google Scholar 

  17. Ashley DM, Faiola B, Nair S, et al.: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exper Med 1997, 186:1177–1182.

    Article  CAS  Google Scholar 

  18. Wallenfriedman MA, Conrad JA, DelaBarre L, et al.: Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 1999, 90:1064–1071.

    PubMed  CAS  Google Scholar 

  19. Lichtor T, Glick RP, Kim TS, et al.: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 1995, 83:1038–1044.

    PubMed  CAS  Google Scholar 

  20. Sampson JH, Archer GE, Ashley DM, et al.: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 1996, 93:10399–10404.

    Article  PubMed  CAS  Google Scholar 

  21. Okada H, Giezeman-Smits KM, Tahara H, et al.: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 1999, 6:219–226.

    Article  PubMed  CAS  Google Scholar 

  22. Visse E, Siesjo P, Widegren B, Sjogren HO: Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther 1999, 6:37–44.

    Article  PubMed  CAS  Google Scholar 

  23. Joki T, Kikuchi T, Akasaki Y, et al.: Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int J Cancer 1999, 82:714–720.

    Article  PubMed  CAS  Google Scholar 

  24. Jachimczak P, Bogdahn U, Schneider J, et al.: The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993, 78:944–951.

    PubMed  CAS  Google Scholar 

  25. Fakhrai H, Dorigo O, Shawler DL, et al.: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 1996, 93:2909–2914.

    Article  PubMed  CAS  Google Scholar 

  26. Fakhrai H, Mantil J, Gramatikova S, et al.: Gene therapy of human gliomas with TGF-b2 antisense gene modified autologous tumor cells. A Phase I Clinical Trial. Proc Am Assoc Cancer Res 2000, 41:543.

    Google Scholar 

  27. DiMeco F, Rhines LD, Hanes J, et al.: Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg 2000, 92:419–427.

    PubMed  CAS  Google Scholar 

  28. Herrlinger U, Kramm CM, Johnston KM, et al.: Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997, 4:345–352.

    PubMed  CAS  Google Scholar 

  29. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocytemacrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997, 8:1065–1072.

    PubMed  CAS  Google Scholar 

  30. Graf MR, Jadus MR, Hiserodt JC, et al.: Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membraneassociated isoform of macrophage colony-stimulating factor. J Immunol 1999, 163:5544–5551.

    PubMed  CAS  Google Scholar 

  31. Okada H, Pollack IF, Lotze MT, et al.: Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK genemodified autologous tumor to elicit an immune response. Hum Gene Ther 2000, 11:637–653.

    Article  PubMed  CAS  Google Scholar 

  32. Kruse CA, Lamb C, Hogan S, et al.: Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther 2000, 7:118–127.

    Article  PubMed  CAS  Google Scholar 

  33. Kruse CA, Emmett M, Savelieva E, et al.: Gene therapy of rat brain tumors with purified HSV-TK Retrovector. Efficacy studies, bystander killing and immune response. Proc Am Assoc Cancer Res 1997, 38:380.

    Google Scholar 

  34. Rosenberg SA, Lotze MT, Muul LM, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or highdose interleukin-2 alone. N Engl J Med 1987, 316:889–897.

    Article  PubMed  CAS  Google Scholar 

  35. Kruse CA, Merchant RE: Cellular therapy of brain tumors: Clinical trials. In Advances in Neuro-Oncology II. Edited by Kornblith PL, Walker MD. Armonk: Futura Publishing; 1997:487–504.

    Google Scholar 

  36. Hayes RL, Koslow M, Hiesiger EM, et al.: Improved long term survival after intracavitary interleukin-2 and lymphokineactivated killer cells for adults with recurrent malignant glioma. Cancer 1995, 76:840–852.

    Article  PubMed  CAS  Google Scholar 

  37. Tsurushima H, Liu SQ, Tuboi K, et al.: Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 1999, 90:536–545. This paper demonstrates the safety and feasibility of using autologous cytotoxic T lymphocytes, activated and expanded ex vivo, then reinjected intratumorally to treat brain tumors.

    PubMed  CAS  Google Scholar 

  38. Quattrocchi KB, Miller CH, Cush S, et al.: Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999, 45:141–157. This paper details the first use of ex vivo activated and expanded T-infiltrating lymphocytes for the treatment of brain tumors. Three of six patients treated were long-term survivors.

    Article  PubMed  CAS  Google Scholar 

  39. Lillehei KO, Mitchell DH, Johnson SD, et al.: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991, 28:16–23.

    Article  PubMed  CAS  Google Scholar 

  40. Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, et al.: A human leukemic T cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res 2000, 60:5731–5739.

    PubMed  CAS  Google Scholar 

  41. Winston KR, Freeman J, Foreman N, et al.: Intrathecal alloreactive cytotoxic T lymphocytes and interleukin-2 for recurrent ependymoma - a phase I study: Proc Am Assoc Neurol Surg/CNS Section Pediatr Neurol Surg 28th Annual Meeting, 1995. Atlanta, GA.

  42. Kruse CA, Lillehei KO, Mitchell DH, et al.: Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci U S A 1990, 87:9577–9581.

    Article  PubMed  CAS  Google Scholar 

  43. Fleshner M, Watkins LR, Redd JM, et al.: A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant 1992, 1:307–312.

    PubMed  CAS  Google Scholar 

  44. Redd JM, Lagarde AC, Kruse CA, Bellgrau D: Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 1992, 34:349–354.

    Article  PubMed  CAS  Google Scholar 

  45. Kruse CA, Schiltz PM, Bellgrau D, et al.: Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 1994, 19:161–168.

    Article  PubMed  CAS  Google Scholar 

  46. Kruse CA, Cepeda L, Owens B, et al.: Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997, 45:77–87. This paper details the use of intratumoral infusions of alloreactive cytotoxic T lymphocytes, sensitized to patient major histocompatibility class, in the treatment of glioma patients. Three of six patients were long-term survivors.

    Article  PubMed  CAS  Google Scholar 

  47. Kruse CA, Rubinstein D: Cytotoxic T lymphocytes reactive to patient major histocompatibility protein for therapy of recurrent primary brain tumors. In Brain Tumor Immunotherapy. Edited by Bigner DD, Becker DP, Cloughsey TF, Liau LM. Totowa: Humana Press; 2001:149–170.

    Google Scholar 

  48. Lampson LA, Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 1986, 136:4054–4062.

    PubMed  CAS  Google Scholar 

  49. Hickey WF, Hsu BL, Kimura H: T-lymphocyte entry into the central nervous system. J Neurosci Res 1991, 28:254–260.

    Article  PubMed  CAS  Google Scholar 

  50. McAfee JG: Migration of immunomodulated cultured lymphocytes in malignant tumors. Progress Clin Biol Res 1990, 355:105–114.

    CAS  Google Scholar 

  51. Kruse CA, Beck LT: Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol Appl Biochem 1997, 25:197–205.

    PubMed  CAS  Google Scholar 

  52. Cesano A, Santoli D: Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms. In Vitro Cell Dev Biol 1992, 28A:648–656.

    Article  PubMed  CAS  Google Scholar 

  53. Cesano A, Visonneau S, Cioe L, et al.: Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy. Cancer Immunol Immunother 1995, 40:139–151.

    PubMed  CAS  Google Scholar 

  54. Visonneau S, Cesano A, Porter DL, et al.: Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000, 6:1744–1754.

    PubMed  CAS  Google Scholar 

  55. Cesano A, Visonneau S, Santoli D: Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res 1995, 55:96–101.

    PubMed  CAS  Google Scholar 

  56. Freeman J, Winston K, Visonneau S, et al.: Cellular immunotherapy of brain tumors involving intratumoral placements of the irradiated TALL-104 cytotoxic T cell line. Proceedings of the American Association of Neurologial Surgeons/CNS Section Pediatric Neurologial Surgery. 28th Annual Meeting 1995. Atlanta, GA.

  57. Paul DB, Read SB, Kleinschmidt-DeMasters BK: Secretion of IFN-g by the 9L gliosarcoma improves the response to local adoptive immunotherapy with alloreactive CTL. 5th Ann meeting, Society Neuro-Oncology, Nov 9–12 2000.

  58. Kattman SJ, Lamb C, Paul DB, et al.: Immunogenicity and tumorigenicity of a 9L gliosarcoma clone producing g-IFN. FASEB J 1999, 13:A297.

    Google Scholar 

  59. Holladay FP, Heitz-Turner T, Bayer WL, Wood GW: Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 1996, 27:179–189. This paper showed the safety of immunization with irradiated glioma cells, ex vivo effector cell expansion, and reinfusion into glioma patients.

    Article  PubMed  CAS  Google Scholar 

  60. Plautz GE, Barnett GH, Miller DW, et al.: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998, 89:42–51.

    Article  PubMed  CAS  Google Scholar 

  61. Plautz GE, Miller DW, Barnett GH, et al.: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000, 6:2209–2218. This paper describes a combined active and passive immunotherapy regimen of vaccination and ex vivo expansion of sensitized lymphocytes. It is one of the first trials to enroll patients upon initial presentation.

    PubMed  CAS  Google Scholar 

  62. Awwad M, North RJ: Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 1988, 65:87–92.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, University of Colorado Health Sciences Center, 4200 E. Ninth Avenue, 80262, Denver, CO, USA

    David B. Paul PhD & Carol A. Kruse PhD

Authors
  1. David B. Paul PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A. Kruse PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paul, D.B., Kruse, C.A. Immunologic approaches to therapy for brain tumors. Curr Neurol Neurosci Rep 1, 238–244 (2001). https://doi.org/10.1007/s11910-001-0024-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0024-8

Keywords

Search

Navigation